Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Quanz M, Bender E, Kopitz C, Grünewald S, Schlicker A, Schwede W, Eheim A, Toschi L, Neuhaus R, Richter C, Toedling J, Merz C, Lesche R, Kamburov A, Siebeneicher H, Bauser M, Hägebarth A.

Mol Cancer Ther. 2018 Nov;17(11):2285-2296. doi: 10.1158/1535-7163.MCT-17-1253. Epub 2018 Aug 16.

PMID:
30115664
2.

An open resource for transdiagnostic research in pediatric mental health and learning disorders.

Alexander LM, Escalera J, Ai L, Andreotti C, Febre K, Mangone A, Vega-Potler N, Langer N, Alexander A, Kovacs M, Litke S, O'Hagan B, Andersen J, Bronstein B, Bui A, Bushey M, Butler H, Castagna V, Camacho N, Chan E, Citera D, Clucas J, Cohen S, Dufek S, Eaves M, Fradera B, Gardner J, Grant-Villegas N, Green G, Gregory C, Hart E, Harris S, Horton M, Kahn D, Kabotyanski K, Karmel B, Kelly SP, Kleinman K, Koo B, Kramer E, Lennon E, Lord C, Mantello G, Margolis A, Merikangas KR, Milham J, Minniti G, Neuhaus R, Levine A, Osman Y, Parra LC, Pugh KR, Racanello A, Restrepo A, Saltzman T, Septimus B, Tobe R, Waltz R, Williams A, Yeo A, Castellanos FX, Klein A, Paus T, Leventhal BL, Craddock RC, Koplewicz HS, Milham MP.

Sci Data. 2017 Dec 19;4:170181. doi: 10.1038/sdata.2017.181.

3.

Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target.

Ellermann M, Eheim A, Rahm F, Viklund J, Guenther J, Andersson M, Ericsson U, Forsblom R, Ginman T, Lindström J, Silvander C, Trésaugues L, Giese A, Bunse S, Neuhaus R, Weiske J, Quanz M, Glasauer A, Nowak-Reppel K, Bader B, Irlbacher H, Meyer H, Queisser N, Bauser M, Haegebarth A, Gorjánácz M.

ACS Chem Biol. 2017 Aug 18;12(8):1986-1992. doi: 10.1021/acschembio.7b00370. Epub 2017 Jul 12.

4.

The 28-year incidence of de novo malignancies after liver transplantation: A single-center analysis of risk factors and mortality in 1616 patients.

Rademacher S, Seehofer D, Eurich D, Schoening W, Neuhaus R, Oellinger R, Denecke T, Pascher A, Schott E, Sinn M, Neuhaus P, Pratschke J.

Liver Transpl. 2017 Nov;23(11):1404-1414. doi: 10.1002/lt.24795.

5.

Functional inhibition of acid sphingomyelinase by Fluphenazine triggers hypoxia-specific tumor cell death.

Klutzny S, Lesche R, Keck M, Kaulfuss S, Schlicker A, Christian S, Sperl C, Neuhaus R, Mowat J, Steckel M, Riefke B, Prechtl S, Parczyk K, Steigemann P.

Cell Death Dis. 2017 Mar 30;8(3):e2709. doi: 10.1038/cddis.2017.130.

6.

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.

Chaturvedi A, Herbst L, Pusch S, Klett L, Goparaju R, Stichel D, Kaulfuss S, Panknin O, Zimmermann K, Toschi L, Neuhaus R, Haegebarth A, Rehwinkel H, Hess-Stumpp H, Bauser M, Bochtler T, Struys EA, Sharma A, Bakkali A, Geffers R, Araujo-Cruz MM, Thol F, Gabdoulline R, Ganser A, Ho AD, von Deimling A, Rippe K, Heuser M, Krämer A.

Leukemia. 2017 Oct;31(10):2020-2028. doi: 10.1038/leu.2017.46. Epub 2017 Jan 31.

7.

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.

Pusch S, Krausert S, Fischer V, Balss J, Ott M, Schrimpf D, Capper D, Sahm F, Eisel J, Beck AC, Jugold M, Eichwald V, Kaulfuss S, Panknin O, Rehwinkel H, Zimmermann K, Hillig RC, Guenther J, Toschi L, Neuhaus R, Haegebart A, Hess-Stumpp H, Bauser M, Wick W, Unterberg A, Herold-Mende C, Platten M, von Deimling A.

Acta Neuropathol. 2017 Apr;133(4):629-644. doi: 10.1007/s00401-017-1677-y. Epub 2017 Jan 25.

PMID:
28124097
8.

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.

Politz O, Siegel F, Bärfacker L, Bömer U, Hägebarth A, Scott WJ, Michels M, Ince S, Neuhaus R, Meyer K, Fernández-Montalván AE, Liu N, von Nussbaum F, Mumberg D, Ziegelbauer K.

Int J Cancer. 2017 Jan 15;140(2):449-459. doi: 10.1002/ijc.30457. Epub 2016 Oct 20.

9.

Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876.

Siebeneicher H, Cleve A, Rehwinkel H, Neuhaus R, Heisler I, Müller T, Bauser M, Buchmann B.

ChemMedChem. 2016 Oct 19;11(20):2261-2271. doi: 10.1002/cmdc.201600276. Epub 2016 Aug 23.

10.

The effect of rod orientation on electrical anisotropy in silver nanowire networks for ultra-transparent electrodes.

Ackermann T, Neuhaus R, Roth S.

Sci Rep. 2016 Sep 28;6:34289. doi: 10.1038/srep34289.

11.

Two-Year Follow-Up Analysis of Telaprevir-Based Antiviral Triple Therapy for HCV Recurrence in Genotype 1 Infected Liver Graft Recipients as a First Step towards Modern HCV Therapy.

Klein F, Neuhaus R, Eurich D, Hofmann J, Bayraktar S, Pratschke J, Bahra M.

Hepat Res Treat. 2016;2016:8325467. doi: 10.1155/2016/8325467. Epub 2016 Apr 18.

12.

Are Metformin Doses Used in Murine Cancer Models Clinically Relevant?

Chandel NS, Avizonis D, Reczek CR, Weinberg SE, Menz S, Neuhaus R, Christian S, Haegebarth A, Algire C, Pollak M.

Cell Metab. 2016 Apr 12;23(4):569-70. doi: 10.1016/j.cmet.2016.03.010. No abstract available.

13.

Identification of novel GLUT inhibitors.

Siebeneicher H, Bauser M, Buchmann B, Heisler I, Müller T, Neuhaus R, Rehwinkel H, Telser J, Zorn L.

Bioorg Med Chem Lett. 2016 Apr 1;26(7):1732-7. doi: 10.1016/j.bmcl.2016.02.050. Epub 2016 Feb 19.

PMID:
26949183
14.

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.

Wengner AM, Siemeister G, Koppitz M, Schulze V, Kosemund D, Klar U, Stoeckigt D, Neuhaus R, Lienau P, Bader B, Prechtl S, Raschke M, Frisk AL, von Ahsen O, Michels M, Kreft B, von Nussbaum F, Brands M, Mumberg D, Ziegelbauer K.

Mol Cancer Ther. 2016 Apr;15(4):583-92. doi: 10.1158/1535-7163.MCT-15-0500. Epub 2016 Feb 1.

15.

BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients.

Sugawara T, Lejeune P, Köhr S, Neuhaus R, Faus H, Gelato KA, Busemann M, Cleve A, Lücking U, von Nussbaum F, Brands M, Mumberg D, Jung K, Stephan C, Haendler B.

Oncotarget. 2016 Feb 2;7(5):6015-28. doi: 10.18632/oncotarget.6864.

16.

Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.

Hartung IV, Hammer S, Hitchcock M, Neuhaus R, Scholz A, Siemeister G, Bohlmann R, Hillig RC, Pühler F.

Bioorg Med Chem Lett. 2016 Jan 1;26(1):186-93. doi: 10.1016/j.bmcl.2015.11.004. Epub 2015 Nov 3.

PMID:
26611920
17.

Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback-Modulation Handles.

Hartung IV, Pühler F, Neuhaus R, Scholz A, Siemeister G, Geisler J, Hillig RC, von Ahsen O, Hitchcock M.

ChemMedChem. 2015 Dec;10(12):2004-13. doi: 10.1002/cmdc.201500442. Epub 2015 Nov 6.

PMID:
26541480
18.

Mutations in Barley Row Type Genes Have Pleiotropic Effects on Shoot Branching.

Liller CB, Neuhaus R, von Korff M, Koornneef M, van Esse W.

PLoS One. 2015 Oct 14;10(10):e0140246. doi: 10.1371/journal.pone.0140246. eCollection 2015.

19.

International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial.

Trappe RU, Choquet S, Dierickx D, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Tarella C, Shpilberg O, Sender M, Salles G, Morschhauser F, Jaccard A, Lamy T, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Leithäuser M, Schlattmann P, Anagnostopoulos I, Raphael M, Riess H, Leblond V, Oertel S; German PTLD Study Group and the European PTLD Network.

Am J Transplant. 2015 Apr;15(4):1091-100. doi: 10.1111/ajt.13086. Epub 2015 Mar 3.

20.

Incidence and long-term survival of patients with de novo head and neck carcinoma after liver transplantation.

Coordes A, Albers AE, Lenarz M, Seehofer D, Puhl G, Pascher A, Neuhaus R, Neuhaus P, Pratschke J, Andreou A.

Head Neck. 2016 May;38(5):707-14. doi: 10.1002/hed.23943. Epub 2015 Jun 25.

PMID:
25521431
21.

A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors.

Fink SE, Gandhi MK, Nourse JP, Keane C, Jones K, Crooks P, Jöhrens K, Korfel A, Schmidt H, Neumann S, Tiede A, Jäger U, Dührsen U, Neuhaus R, Dreyling M, Borchert K, Südhoff T, Riess H, Anagnostopoulos I, Trappe RU.

Am J Transplant. 2014 Nov;14(11):2577-87. doi: 10.1111/ajt.12858. Epub 2014 Aug 4.

22.

Successful Treatment of Chronic Hepatitis E After an Orthotopic Liver Transplant With Ribavirin Monotherapy.

Klein F, Neuhaus R, Hofmann J, Rudolph B, Neuhaus P, Bahra M.

Exp Clin Transplant. 2015 Jun;13(3):283-6. doi: 10.6002/ect.2013.0286. Epub 2014 Apr 28.

23.

Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.

Zimmermann H, Weiland T, Nourse JP, Gandhi MK, Reinke P, Neuhaus R, Karbasiyan M, Gärtner B, Anagnostopoulos I, Riess H, Trappe RU, Oertel S.

J Immunol Res. 2014;2014:264723. doi: 10.1155/2014/264723. Epub 2014 Feb 10.

24.

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.

Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, Scholz A.

Neoplasia. 2013 Oct;15(10):1161-71.

25.

Twenty-year longitudinal follow-up after orthotopic liver transplantation: a single-center experience of 313 consecutive cases.

Schoening WN, Buescher N, Rademacher S, Andreou A, Kuehn S, Neuhaus R, Guckelberger O, Puhl G, Seehofer D, Neuhaus P.

Am J Transplant. 2013 Sep;13(9):2384-94. doi: 10.1111/ajt.12384. Epub 2013 Aug 5.

26.

Baseline differential blood count and prognosis in CD20-positive post-transplant lymphoproliferative disorder in the prospective PTLD-1 trial.

Zimmermann H, Choquet S, Moore J, Salles G, Morschhauser F, Lamy T, Jaccard A, Horst HA, Leithäuser M, Dührsen U, Reinke P, Lebranchu Y, Neuhaus R, Lehmkuhl H, Tarella C, Schlattmann P, Riess H, Leblond V, Trappe RU.

Leukemia. 2013 Oct;27(10):2102-5. doi: 10.1038/leu.2013.110. Epub 2013 Apr 15. No abstract available.

PMID:
23584565
27.

Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.

Hartung IV, Hitchcock M, Pühler F, Neuhaus R, Scholz A, Hammer S, Petersen K, Siemeister G, Brittain D, Hillig RC.

Bioorg Med Chem Lett. 2013 Apr 15;23(8):2384-90. doi: 10.1016/j.bmcl.2013.02.028. Epub 2013 Feb 14.

PMID:
23474388
28.

Genetic variants of STAT-4 affect the development of graft fibrosis after liver transplantation for HCV-induced liver disease.

Eurich D, Boas-Knoop S, Struecker B, Neuhaus R, Neuhaus P, Bahra M.

Transplantation. 2013 Jan 15;95(1):203-8. doi: 10.1097/TP.0b013e318277e2f6.

PMID:
23202532
29.

YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease.

Eurich D, Neumann UP, Boas-Knoop S, Neuhaus R, Kiessling A, Yahyazadeh A, Trautwein C, Wasmuth H, Puhl G, Neuhaus P, Bahra M.

J Gastroenterol Hepatol. 2013 Jan;28(1):153-60. doi: 10.1111/j.1440-1746.2012.07270.x.

PMID:
22989351
30.

Role of mannose-binding lectin-2 polymorphism in the development of acute cellular rejection after transplantation for hepatitis C virus-induced liver disease.

Eurich D, Boas-Knoop S, Yahyazadeh A, Neuhaus R, Somasundaram R, Ruehl M, Puhl G, Neuhaus P, Neumann UP, Bahra M.

Transpl Infect Dis. 2012 Oct;14(5):488-95. doi: 10.1111/j.1399-3062.2012.00747.x. Epub 2012 Jun 1.

PMID:
22650645
31.

Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy.

Eurich D, Boas-Knoop S, Bahra M, Neuhaus R, Somasundaram R, Neuhaus P, Neumann U, Seehofer D.

Transplantation. 2012 Mar 27;93(6):644-9. doi: 10.1097/TP.0b013e318244f774.

PMID:
22411462
32.

Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.

Zimmermann H, Reinke P, Neuhaus R, Lehmkuhl H, Oertel S, Atta J, Planker M, Gärtner B, Lenze D, Anagnostopoulos I, Riess H, Trappe RU.

Cancer. 2012 Oct 1;118(19):4715-24. doi: 10.1002/cncr.27482. Epub 2012 Mar 5.

33.

Transforming growth factor-β1-gene polymorphism in the development of kidney disease after liver transplantation.

Eurich D, Neumann UP, Boas-Knoop S, Neuhaus R, Bahra M, Neuhaus P, Schmitz V.

Transplantation. 2012 Mar 15;93(5):555-60. doi: 10.1097/TP.0b013e318242be0b.

PMID:
22366990
34.

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.

Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P, Neuhaus R, Lehmkuhl H, Horst HA, Salles G, Morschhauser F, Jaccard A, Lamy T, Leithäuser M, Zimmermann H, Anagnostopoulos I, Raphael M, Riess H, Choquet S; German PTLD Study Group; European PTLD Network.

Lancet Oncol. 2012 Feb;13(2):196-206. doi: 10.1016/S1470-2045(11)70300-X. Epub 2011 Dec 13.

PMID:
22173060
35.

Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era.

Pfiffer TE, Seehofer D, Nicolaou A, Neuhaus R, Riess H, Trappe RU.

Tumori. 2011 Jul-Aug;97(4):436-41. doi: 10.1700/950.10394.

PMID:
21989430
36.

Re: "comparison of the exposure rate of wrapped hydroxyapatite (Bio-Eye) versus unwrapped porous polyethylene (Medpor) orbital implants in enucleated patients".

Nasser QJ, Blaydon SM, Connor MA, Nakra T, Shepler TR, Neuhaus RW, Shore JW.

Ophthalmic Plast Reconstr Surg. 2011 Sep-Oct;27(5):391; author reply 391-2. doi: 10.1097/IOP.0b013e318226420e. No abstract available.

PMID:
21904174
37.

Mycophenolate mofetil monotherapy in liver transplantation: 5-year follow-up of a prospective randomized trial.

Schmeding M, Kiessling A, Neuhaus R, Heidenhain C, Bahra M, Neuhaus P, Neumann UP.

Transplantation. 2011 Oct 27;92(8):923-9. doi: 10.1097/TP.0b013e31822d880d.

PMID:
21832958
38.

Liver transplant from a donor with occult HEV infection induced chronic hepatitis and cirrhosis in the recipient.

Schlosser B, Stein A, Neuhaus R, Pahl S, Ramez B, Krüger DH, Berg T, Hofmann J.

J Hepatol. 2012 Feb;56(2):500-2. doi: 10.1016/j.jhep.2011.06.021. Epub 2011 Jul 26.

39.

Association of mannose-binding lectin-2 gene polymorphism with the development of hepatitis C-induced hepatocellular carcinoma.

Eurich D, Boas-Knoop S, Morawietz L, Neuhaus R, Somasundaram R, Ruehl M, Neumann UP, Neuhaus P, Bahra M, Seehofer D.

Liver Int. 2011 Aug;31(7):1006-12. doi: 10.1111/j.1478-3231.2011.02522.x. Epub 2011 Apr 15.

PMID:
21733090
40.

IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment.

Hinrichs C, Wendland S, Zimmermann H, Eurich D, Neuhaus R, Schlattmann P, Babel N, Riess H, Gärtner B, Anagnostopoulos I, Reinke P, Trappe RU.

Transpl Int. 2011 Sep;24(9):892-903. doi: 10.1111/j.1432-2277.2011.01282.x. Epub 2011 Jun 11.

41.

Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.

Eurich D, Bahra M, Berg T, Boas-Knoop S, Biermer M, Neuhaus R, Neuhaus P, Neumann U.

Exp Clin Transplant. 2011 Feb;9(1):1-6.

42.

Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation.

Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Berg T, Neuhaus R, Neuhaus P, Neumann UP, Bahra M.

Liver Transpl. 2011 Mar;17(3):289-98. doi: 10.1002/lt.22235.

43.

Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus--induced liver disease.

Eurich D, Bahra M, Boas-Knoop S, Lock JF, Golembus J, Neuhaus R, Neuhaus P, Neumann UP.

Liver Transpl. 2011 Mar;17(3):279-88. doi: 10.1002/lt.22190.

44.

Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study.

Yahyazadeh A, Beckebaum S, Cicinnati V, Klein C, Paul A, Pascher A, Neuhaus R.

Transpl Int. 2011 May;24(5):441-50. doi: 10.1111/j.1432-2277.2011.01222.x. Epub 2011 Feb 5.

45.

ELISA-based detection of C4d after liver transplantation--a helpful tool for differential diagnosis between acute rejection and HCV-recurrence?

Schmeding M, Kienlein S, Röcken C, Neuhaus R, Neuhaus P, Heidenhain C, Neumann UP.

Transpl Immunol. 2010 Aug;23(4):156-60. doi: 10.1016/j.trim.2010.06.002. Epub 2010 Jun 14.

PMID:
20558292
46.

Liver transplantation for alcohol-related cirrhosis: a single centre long-term clinical and histological follow-up.

Schmeding M, Heidenhain C, Neuhaus R, Neuhaus P, Neumann UP.

Dig Dis Sci. 2011 Jan;56(1):236-43. doi: 10.1007/s10620-010-1281-7. Epub 2010 May 25.

PMID:
20499174
47.

Aging of the liver graft and functional quality in the absence of recurrent disease: a 10 year histological follow-up.

Schmeding M, Sauer I, Hartwig K, Theruvath T, Pratschke J, Neuhaus R, Neuhaus P, Neumann UP.

Ann Transplant. 2010 Jan-Mar;15(1):5-13. Review.

PMID:
20305312
48.

Safety of mycophenolate mofetil monotherapy in patients after liver transplantation.

Kamphues C, Bova R, Röcken C, Neuhaus R, Pratschke J, Neuhaus P, Neumann UP.

Ann Transplant. 2009 Oct-Dec;14(4):40-6.

PMID:
20009154
49.

BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients.

le Coutre P, Reinke P, Neuhaus R, Trappe R, Ringel F, Lalancette M, Hemmati PG, Dörken B, Daniel PT.

Eur J Haematol. 2010 Jan 1;84(1):26-33. doi: 10.1111/j.1600-0609.2009.01357.x. Epub 2009 Oct 3.

PMID:
19799626
50.

Immunization of liver and renal transplant recipients: a seroepidemiological and sociodemographic survey.

Chesi C, Günther M, Huzly D, Neuhaus R, Reinke P, Engelmann HB, Mockenhaupt FP, Bienzle U.

Transpl Infect Dis. 2009 Dec;11(6):507-12. doi: 10.1111/j.1399-3062.2009.00436.x. Epub 2009 Aug 18.

PMID:
19695000

Supplemental Content

Loading ...
Support Center